AN2 Therapeutics (ANTX) Status update summary

Strategic rationale and market opportunity

• Epetraborole is being developed for polycythemia vera (PV) to address a significant unmet need for oral, red cell-specific therapies, based on compelling data from non-PV patients.

• The U.S. PV market is estimated at 150,000–155,000 patients, representing a substantial opportunity.

• Durable hematocrit control is challenging with current therapies, and no oral therapies specifically target erythrocytosis.

• The decision to advance epetraborole is supported by clinical evidence showing early, controlled, and sustained hematocrit reduction with favorable safety and tolerability.

• Multiple value-creating milestones are anticipated over the next two years, including Phase 2 topline data.

Clinical data and trial design

• Epetraborole demonstrated consistent, dose-dependent, and reversible hematocrit control in multiple studies, with minimal impact on white blood cells and platelets.

• Phase 2 trial will include open-label and placebo-controlled cohorts, focusing on phlebotomy-dependent PV patients, with endpoints aligned to recent pivotal studies.

• The study will assess efficacy, optimize dosing, evaluate safety and tolerability, and measure patient-reported outcomes.

• Initial sentinel cohort data are expected in Q4 2026, with ongoing updates through 2027.

• Platelet and WBC counts remained stable in prior trials, indicating erythroid-lineage selectivity.

Mechanism of action and differentiation

• Epetraborole is hypothesized to act via indirect inhibition of globin synthesis, selectively blocking red blood cell production without affecting other lineages.

• This mechanism allows for dose titration and reduces risk of cytopenias common with current therapies, potentially offering molecular as well as hematologic benefits.

• Once-daily oral administration and objective endpoints enable timely data readouts.